Reversible ATP-competitive JNK inhibitor (IC50 values 40 nM, 40 nM, and 90 nM for JNK1, JNK2 and JNK3, respectively) with >20-fold selectivity vs. a range of kinases and enzymes tested. SP600125 caused G2/M cell cycle arrest and elevation of cyclin B1 and p27(kip), thereby inhibiting cell proliferation and increasing apoptosis in multiple cell lines. Moreover, SP600125 dose dependently inhibits phosphorylation of c-Jun, the expression of inflammatory genes COX-2, IL-2, IFN-γ, TNF-α, and prevents activation and differentiation of primary human CD4 cell cultures; SP600125 has proven to be a useful tool for isolation, generation, derivatization and stabilization of naive human pluripotent stem cells in so called NHSM conditions developed at the Weizmann Institute of Science.

*Promotion: SP 600125 is also part of Inhibitor Set(s):

KEYWORDS: SP 600125 | supplier | JNK inhibitor | NSC 75890 | SP600125 | NSC75890 | CAS [129-56-6] | [67072-00-8] | MAPK | c-Jun | kinase | Inhibitor | ATP competitive | G2/M | arrest | proliferation | apoptosis | NHSM | pluripotent | stem cell | hPSC | derivatisation | Weizmann Institute